Communiqués Alligator Bioscience AB London S.E.

Actions

0RK9

SE0024173637

Recherche biotechnologique et médicale

Marché Fermé - London S.E. Autres places de cotation 12:55:48 18/12/2025			Varia. 5j.	Varia. 1 janv.
0,3209 ^SEK	-99,99%		+505,47%	-0,28%

23/07	Prudence à la Bourse de Stockholm avant la décision de la BCE, l'indice OMXS30 inchangé	FW
23/07	Neuf actions ont atteint un nouveau plus bas sur 52 semaines aujourd'hui à la Bourse de Stockholm	FW

Communiqués

23/07	Notice of extraordinary general meeting in Alligator Bioscience AB	AQ
23/07	Alligator discontinues independent development of mitazalimab for a strategic refocus on the HLX22 project, announces a rights issue of units of approximately SEK 125.6 million and raises bridge loans	AQ
02/07	Alligator announces first patient dosed in investigator-initiated study of intratumoral mitazalimab in early-stage breast cancer	AQ
08/06	Alligator Bioscience comments on Henlius update on global phase 3 trial with HLX22	AQ
22/05	Alligator Bioscience comments on Henlius update on long-term follow-up data for HLX22	AQ
08/05	Alligator Bioscience (Q1 2026 Review): Pragmatic Path to Phase III	AQ
06/05	Bulletin from the annual general meeting in Alligator Bioscience AB on 6 May 2026	AQ
05/05	Alligator Bioscience AB reports financial results for the period 1 January – 31 March 2026 and provides a business update	AQ
28/04	Invitation to Alligator Bioscience's Earnings Call on 5 May 2026	AQ
28/04	Invitation to Alligator Bioscience’s earnings call on 5 May 2026	AQ
23/04	Alligator Bioscience comments on Henlius presentation of HLX49 preclinical data at AACR 2026	AQ
20/04	New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026	AQ
13/04	Alligator Bioscience provides an update on mitazalimab	AQ
10/04	Alligator Bioscience provides an update on mitazalimab	AQ
31/03	Change in number of shares and votes in Alligator Bioscience AB	AQ
30/03	Alligator Bioscience : Proposal for resolution on authorization regarding issues (Proposal for resolution on authorization regarding issues)	PU
30/03	Alligator Bioscience : The Nomination Committee’s proposals and reasoned statement (The Nomination Committees proposals and reasoned statement )	PU
30/03	Alligator Bioscience : Power of Attorney form (Power of Attorney form )	PU
30/03	Notice of annual general meeting in Alligator Bioscience AB	AQ
27/03	The Nomination Committee's Proposals Regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)	AQ
27/03	The Nomination Committee’s proposals regarding the Board of Directors for the Annual General Meeting in Alligator Bioscience AB (publ)	AQ
26/03	Alligator Bioscience publishes Annual Report for 2025	AQ
20/03	Alligator Bioscience AB announces outcome of exercise of warrants series TO 14	AQ
18/03	New data from Investigator‑Initiated Study Evaluating Alligator Bioscience's Mitazalimab to be Presented at AACR Annual Meeting 2026	AQ
18/03	New data from investigator‑initiated study evaluating Alligator Bioscience’s mitazalimab to be presented at AACR Annual Meeting 2026	AQ